Kardigan, Inc. (KARD)

Kardigan is a well-funded but pre-revenue clinical-stage cardiovascular biotech: the June 2026 IPO left $660.7M of cash and investments, no debt and no current going-concern doubt, but zero revenue, roughly $215M of annual cash burn, binary Phase 2/3 catalysts and substantial future dilution keep the fundamental profile speculative, high-volatility and dependent on clinical data due in the first half of 2027.

No actionable short-term catalyst: the official-PR channel failed extraction, and third-party discovery surfaced only routine governance/compensation housekeeping (board refresh 9/29–30; director option grant 10/1) plus fully digested items (Q2 2026 print 8/11; September Russell additions). Media sentiment measured neutral-to-mild (~+0.07 on three board-change items in the 14-day window) with an indeterminate delta (baseline too thin — two unique on-topic scored items), no retail coverage, and a clean Red-Flag Screen — a quiet, absent setup.

Mixed, bounce-driven tape. Trend frame: price 15.64 is back above the SMA20 (15.51), EMA9 (14.74) and the short-term DEMA/TEMA/WMA cluster (13.94-14.93) after a 3-session rally off the 2026-10-07 low of 12.23, but it remains below the EMA21 (15.79) and well below the SMA50 (18.59) - the intermediate structure is still down from the July highs near 25 (SMA200 not yet computable; June-2026 IPO). Momentum: RSI14 45.64 recovering from ~30, Williams %R -22.76, MACD histogram positive and expanding (+0.15) though the MACD line (-1.30) is still deeply negative; ADX14 21.71 = no strong trend either way. Volatility elevated: ATR14 1.43 (~9.1% of price); StdDev20 1.49. Volume/liquidity adequate: avgDollarVolume20 ~$15.2M; last-3-session regular dollar volume ~$13.6M. Feed fresh (last bar 2026-10-09). No entry plan is built: fundamentalScore 2 and qualitativeScore 2 both fail the >=3 override gates, so per the workflow the trade plan is skipped and the action is Do Nothing.